




Background: Acute care utilization at the end of life among those with advanced cancer is increasing. Women with metastatic breast cancer (MBC) often remain in active treatment until close to death, often receiving futile chemotherapy and sometimes requiring emergency department (ED) visits that may result in admission to the hospital. Palliative care (PC) programs have aimed to reduce overuse by attempting to control symptoms and distress that may result in a visit to the ED or admission to the hospital. 
Purpose: Describe characteristics of women with MBC receiving care at an outpatient National Cancer Institute designated breast center, describe their acute care utilization during the last six months of life and examine those outcomes in view of specific demographic, disease and treatment factors.
Methods and Analysis: Retrospective chart review according to protocolized abstraction of 100 MBC patients who died between 2010 and 2012 from one large urban practice. Records were reviewed for demographics, disease and treatment characteristics and acute care utilization of women with MBC during the last six months of life. Descriptive analysis and multiple regression was employed to test associations between age, race and income on each of the explored factors. 
Findings: 69% of all MBC patients visited the ED in the last 6 months of life and 26% died in the acute care setting. Of patients on active chemotherapy, nearly ½ of the ED visits were within 7 days of chemotherapy administration. 52% percent of patients received chemotherapy in the last 6 months of life for a total of 3.6 sequential lines during MBC treatment. There was no significant difference between PC (n=15) and Non-PC patients (n=85); suggesting that a “PRN” approach to PC may not have an impact on utilization of acute care resources. 
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Breast cancer, the most common cancer among women in the US, has experienced tremendous advancement as those diagnosed with the disease are living longer, healthier lives. Of the annual 40,450 breast cancer deaths in the US, virtually all result from women with metastatic breast cancer (MBC).1 Although at a point in time only 6% of all breast cancer presentations are of MBC, approximately 30% of all women diagnosed with breast cancer will eventually develop metastatic disease.2 It is estimated that there are approximately 50,000 incident cases of MBC annually with a prevalence of approximately 160,000 US women living with MBC.3 The cost of MBC to society overall is tremendous, not only in dollars for treatment, but also in lost productivity, caregiver costs and out of pocket expenses incurred with chronic, progressive illness. A recent model analysis of cost of illness for US MBC care incorporating treatment/supportive care, lost productivity, care provider's cost and incidentals defined as "societal burden", in 2010 dollars, was 2.4 billion dollars/year or $98,571 per patient year.3 
MBC is perhaps the prototype for the paradigm of active cancer treatment until close to death. Median survival from diagnosis of MBC is 24 to 52 months4, with little known about predictive or prognostic factors for response to treatment and ultimate survival. Ongoing analysis from several MBC cohorts over the course of several decades has shown a progressive increase in MBC survival, attributed in part to more aggressive systemic therapies. Because there are not only survival improvements, but quality of life and symptom reduction benefit with MBC chemotherapy5, large numbers of women receive relatively aggressive chronic cancer therapy. Ironically, patients are often counseled that MBC is increasingly a "chronic" disease, somewhat diminishing the seriousness of the diagnosis. The downside of the success of active treatment for MBC is that women with MBC often remain in active treatment until close to death, long after treatment is futile. Active treatment results in side effects and hospitalizations. PC promotes pain and symptom relief, improves patient/caregiver/family satisfaction, facilitates earlier transition to hospice, decreases emergency department (ED) visits, lowers health care costs without affecting mortality and extends survival.6–10 However, due to the heterogeneity of the disease and patients’ and oncologists’ not wanting to give up “hope”, most women are not enrolled in PC that provides physical and emotional support and a more personalized use of specialty providers integrated with active treatment. 
This retrospective chart review will provide insight into the utilization of acute care services during the last six months of life among a deceased cohort of individuals with MBC who received cancer care at the University of Pittsburgh Medical Center (UPMC) Womens Cancer Center at Magee Womens Hospital. PC at this setting is delivered in the outpatient setting on an as needed basis, not integrated into ongoing care. The purpose of our study was to describe characteristics of women with MBC receiving care at an outpatient National Cancer Institute (NCI) designated breast center, describe their acute care utilization during the last six months of life and to examine those outcomes in view of specific demographic and treatment factors. We also wanted to examine if PC delivered on an “as needed” basis influenced the utilization of ED and acute care services at the end of life.


Specifically, we aim to 
1) Describe patient, disease, treatment characteristics and acute care utilization of women with MBC during the last six months of life.
2) Examine the influence of age, race and income on acute care utilization among women with MBC during the last six months of life.
Hypothesis: Younger women will utilize more regimens of chemotherapy, utilize the ED more often and have more acute care deaths than older women.
3) Compare acute care utilization in the last six months among women with MBC according to patients enrolled in outpatient palliative care (PC) and those not enrolled in outpatient PC.
Hypothesis: Women enrolled in outpatient PC will utilize fewer regimens of chemotherapy, utilize the ED less often and have fewer acute care deaths than their non-PC counterparts. 
2.0 	BACKGROUND
2.1	Cost of Cancer care
The financial costs of cancer care are a burden to people diagnosed with cancer, their families and society as a whole. National cancer care expenditures have been steadily increasing in the US. These costs are likely to increase as new, more advanced treatments are adopted as standards of care. National costs for all breast cancer care in 2010 were 16.5 billion dollars11 and 2.4 billion dollars for MBC.3 These figures do not include other types of costs, such as lost productivity and caregiver costs, also contributing to the overall financial burden of cancer. In a survey of family members of seriously ill patients, 31% reported loss of most of the family savings, 29% reported loss of the family’s major source of income and 34% of patients required significant caregiving assistance from a family member.12 
2.2	Cost of end of life care
Health care costs have been a major focus of the nation. Currently, health care expenditures in the US are about 18 percent of GDP, and this share is projected to rise sharply. If health care costs continue to grow at historical rates, by 2021, health care costs will reach nearly one-fifth (20%) of GDP.13 Observations that  high cost care is not associated with improved outcomes14,15 have prompted efforts to achieve more value for health care dollars.16,17 Consequently, health care reform in the US is focused on identification of cost-effective interventions and models of delivery that not only improve outcomes but contain costs. Care near the end of life consumes a disproportionate share of costs and is therefore a logical target for efforts to promote value.18,19  As a result, there has been recognition among health care leaders and policy makers of the importance of high quality end of life care that includes end-of-life decision making, pain and symptom management, psychosocial support and hospice care20 in an effort to not only reduce burdensome costs but also improve the quality of life of the dying patient their family. 
2.3	Cancer mortality
Despite significant improvements in cancer treatment, approximately half of all patients with cancer die of their disease, and one third of cancer deaths happen within 6 months of diagnosis.21 Of the annual 40,450 breast cancer deaths in the United States (US), virtually all result from women with MBC.1 Although at a point in time only 6% of all breast cancer presentations are of MBC, approximately 30% of all women diagnosed with breast cancer will eventually develop metastatic disease.2 It is estimated that there are approximately 50,000 incident cases of MBC annually with a prevalence of approximately 160,000 US women living with MBC.3 More often in the US than in other countries, the trend among patients at the end of life has been persistent use of chemotherapy near the end of life and later hospice referrals.22,23 End of life care frequently involves aggressive intervention resulting in high cost and poor quality.24,25 The use of aggressive end of life cancer care results in intensive use of chemotherapy, low rates of hospice use, and interventions that result in ED visits, hospitalization, or intensive care unit (ICU) admissions.26 
2.4	Metastatic breast cancer
Based on rates from 2007-2009, 12.38% or 1 in 8 women born today will be diagnosed with breast cancer at some time during their lifetime. From 2005-2009, the median age at diagnosis for breast cancer was 61 years of age. Approximately 0.0% were diagnosed under age 20; 1.8% between 20 and 34; 9.9% between 35 and 44; 22.5% between 45 and 54; 24.8% between 55 and 64; 20.2% between 65 and 74; 15.1% between 75 and 84; and 5.7% 85+ years of age.2 However, widespread use of screening, along with treatment advances, has been credited with significantly reducing breast cancer mortality. From 2005-2009, the median age at death for breast cancer was 68 years of age.  There were no patients  under age 20; 0.9% between 20 and 34; 5.6% between 35 and 44; 14.8% between 45 and 54; 21.4% between 55 and 64; 19.9% between 65 and 74; 22.0% between 75 and 84; and 15.5% 85+ years of age.2 
2.5	Metastatic breast cancer treatment
Treatment for metastatic breast cancer focuses on length and quality of life. Women with MBC often remain in active treatment up until or close to death. There is no single standard of care for patients with MBC, as women treatment plans require an individualized approach. Due to the heterogeneity of breast cancer treatment response to chemotherapy, the 2012 National Comprehensive Cancer Network (NCCN) recommendation for systemic metastatic chemotherapy endorses sequential chemotherapy of at least 3 regimens (or a poor performance status) before recommendation of  supportive care alone.27  Treatment for MBC is guided by many factors including specific tumor biology, growth rate of disease, presence of visceral metastases, history of prior therapy and response, risk for toxicity and, most importantly, patient preference.4 These treatments include chemotherapy, biologic therapy and supportive care most commonly provided on a weekly to monthly schedule on an outpatient basis in cancer centers throughout the US. During this time, the therapeutic regimen will typically change multiple times. Despite decades of clinical cancer research, the true impact of treatment beyond the third line of chemotherapy on the survival outcome of metastatic breast cancer patients is still being investigated. In routine clinical practice, an increasing number of women asking for further treatment after progression receive subsequent lines. Recent studies have indicated that chemotherapy beyond the second line may be beneficial in a significant subset of women.28,29 For the majority of patients, the benefit of more than three lines of chemotherapy for metastatic disease is minimal, if any. However, many patients still receive several lines of chemotherapy, sometimes received up until or close to death. With substantial variations in growth rate and responsiveness to therapy, the clinical outcome and prognosis in each patient does not always conform to the published data, which is based on population averages. 
2.6	Side effects of treatment
Active treatment in this vulnerable population often creates side effects and/or medical emergencies requiring ED visits. During this time in the months leading up until death, this unique group of patients typically experiences a multitude of disease and treatment related side effects, such as nausea and vomiting, dehydration, infection, altered mental status and shortness of breath resulting in the need for urgent care in the ED setting. Reducing ED visits and hospitalizations is associated with greater quality of life at the end of life.30 
Providing quality care should be a priority of all healthcare professionals. Particular attention to quality of care is especially important in a population of patients with cancer nearing the end of life because of the potential for misuse, overuse or neglect of available services. A byproduct of aggressive MBC treatment until death without integrated PC can be an increased symptom burden causing an increased rate of ED visits, with resultant burden and stress at the end of life. 
2.7	Uncertainty in prognosis
Both patients and physicians struggle with prognosis; physicians struggle with delivering prognosis and patients struggle with acceptance of prognosis in advanced stage disease. The heterogeneity of MBC treatment makes prognostication difficult and complicates providers’ ability to determine when active treatment should be terminated and/or PC should commence. MBC does not have the same predictability in prognosis as other metastatic cancers such as non-small cell lung cancer or metastatic pancreatic cancer. Some women may experience minimal disease that remains well controlled while others may experience more widespread disease that is unresponsive to chemotherapy. This clinical reality presents a paradox – MBC is still not “curable” but the length of time diagnosed with metastatic disease is increasing, resulting in evolving expectations for life extending treatment, as well as supportive and informational needs.31 Consequently, variations in disease trajectories may result in the reluctance of a physician to refer a patient to a program of PC. Ultimately, oncologists serve as gatekeepers32 to PC referral and may be reluctant to make a referral for fear of destroying a patient’s hope.33 
Additionally, patients may find it difficult to understand prognosis.  Oncologists are poor prognosticators and often do not discuss prognosis with their patient. In a study assessing physicians’ discussion of prognosis among patients receiving palliative chemotherapy, only 39% of medical oncologists’ discussed prognosis.34 Furthermore, in a study of hospitalized patients for whom death was believed to be imminent, families reported that the attending physician never discussed the possibility of death 62% of the time and no one on the medical team discussed the possibility of death with cancer patients in 39% of the cases.35 The ED is considered a less than ideal location for end-of-life discussions  due to the chaotic nature and care by providers with little to no formal end-of life care education36,37, poor communication skills when discussing goals of care with patients and families, lack of familiarity with available referrals to palliative medicine specialists and resources and discomfort with appropriate withholding or withdrawing of care.38 Additionally, ED care is expensive and consequently a major component of escalating costs of care at the end of life.25,39,40,41 Despite being ill-equipped to provide end-of-life care, EDs in the United States are increasingly utilized by patients with cancer for disease or treatment related problems.42,43 However, we do not know patterns of ED utilization among women with metastatic breast cancer during the last six months of life. 
2.8	Emergency department utilization
The ED is a critical site of care delivery and a safety net of the acutely and chronically ill. Despite being ill-equipped to provide end-of-life care, EDs in the United States are increasingly utilized by patients with cancer for disease or treatment related problems.42,43 Particularly, patients with advanced and end-stage disease in need of symptom  management and pain relief often present to the ED.39,44–46 Despite this, the ED is considered a less than ideal location for end-of-life due to the chaotic nature and care by providers with little to no formal end-of life care education36,37, poor communication skills when discussing goals of care with patients and families, lack of familiarity with available referrals to palliative medicine specialists and resources and discomfort with appropriate withholding or withdrawing of care.38 Emergency physicians are skilled at recognizing life threatening conditions and are less comfortable facilitating the dying process when death is inevitable. Furthermore, ED care is expensive and consequently a major component of escalating costs of care at the end of life.47Understanding reasons for and outcomes of ED utilization are important in improving the quality of care among individuals with advanced illness. 
2.9	chemotherapy utilization
Palliative chemotherapy is increasingly given near death. More than 20% of patients with metastatic cancer receiving Medicare started a new chemotherapy treatment regimen in the 2 weeks prior to death.22 In Italy, 23% of patients with incurable cancer received chemotherapy within 30 days of death.48 In a community practice in the US, chemotherapy for patients with lung cancer was given within 30 days of death for 43% and 14 days of death for 20% of patients.49 Studies worldwide consistently show that patients with cancer were generally willing to undergo aggressive treatment with major adverse effects for a very small chance of benefit, different from what their physicians and nurses would choose.50 The appropriate role of chemotherapy near the end of life is complex. Utilization of chemotherapy at the end of life requires a sophisticated oncological assessment, focusing on the patients goals of care as well as balancing perspectives of the patient and oncologist.51 Chemotherapy for metastatic solid tumors such as lung, breast, colon or prostate cancer rarely if ever cures patients. Instead, chemotherapy is given in hopes of improving disease-free or overall survival, relieve symptoms and improve quality of life.51 Over the course of several decades, there have been tremendous survival improvements, as well as quality of life and symptom reduction benefit with MBC chemotherapy.5 Consequently, these large numbers of women receive relatively aggressive chronic cancer therapy, often remaining in active treatment until close to death without integrated PC. The 2012 NCCN recommendation for systemic metastatic chemotherapy endorses sequential chemotherapy of at least 3 regimens (or a poor performance status) before recommendation of  supportive care alone.27
2.10	Site of death
The place of death  is of considerable interest worldwide.52 Not only does the place of death impact quality of death and dying53, but there are many other indirect and direct costs and considerations associated with the place of death and dying.54  Public opinion surveys in the US report that the majority of people would prefer to die at home if they were terminally ill.55 Despite this reported preference of dying at home among the general population, in reality, most die in an institutional setting.56,57 Although much attention has focused on the high cost of dying in hospitals and nursing homes58, home-based dying often involves significant out-of-pocket costs in addition to greater assistance from family/caregivers.59,60 Most end-of-life care in the home is provided by family caregivers, often with little assistance from others, including formal home care providers.59,61 However, a shift from hospital to home-based death is happening in the US, as well as Britain and Canada.61–63 There is conflicting evidence about the influence of race/ethnicity on the use of the ICU at the end-of-life and little is known about the influence of socioeconomic status. 
2.11	Sociodemographic factors in Cancer
It is known that African Americans utilize hospice at a lower rate than white Americans and that care preference at the end of life is usually for aggressive, rather than comfort care even with little chance of therapeutic success.64,65 These differences may be reflective of deeply held cultural values that are religiously based and it may be culturally insensitive to attempt to “change” these beliefs.66 In addition, these preferences are hardly unique to African Americans, particularly in today’s cancer care environment. Today’s paradigm of treatment for patients with advanced cancer is often relatively aggressive chemotherapies and biotherapies until the end of life. 
Interestingly, despite the evidence that MBC treatment improves survival and quality of life and evidence that African American patients desire aggressive therapy at end of life,67–69 one analysis of MBC treatment for women from low-income zip codes found 45% of the low-income population had no MBC treatment.70 Reasons for non-treatment were not explored.   Furthermore, emotional and physical distress is disproportionately higher among AA women receiving breast cancer treatment, than white or higher income women.71 It is not known if these symptom disparities exist in MBC as well.  
The extrication of race and income in evaluation of outcomes among women with breast cancer in the United States is virtually impossible.72 Bradley et al.73 attempted to evaluate breast cancer outcomes according to income using census tract categorization instead of race. In this analysis, low socio-economic status, not race, was associated with worse breast cancer outcomes. However, all attempts to look at low income status as an independent variable in breast cancer outcome data include a disproportionate number of minority women due to the poverty rates of US African Americans. Without specific categorization of race and income, the independent effect of income can never truly be analyzed. 
Income has not been studied to the extent that race has been evaluated in relation to distress and needs of care at the end of life. There is a relationship between low income levels and high levels of cancer related distress, with those reporting distress and symptom burden often not taking advantage of available services.74   
2.12	Palliative Care
The goal of PC as defined by the American Academy of Hospice and Palliative Medicine is “to prevent and relieve suffering and to support the best possible quality of life for patients facing life-threatening or debilitating illness and their families, regardless of the stage of the disease or the need for other therapies”.75 The World Health Organization defines PC as “an approach that improves the quality of life of patients and their families facing the problems associated with life-threatening illness, through the prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain and other problems, physical, psychosocial and spiritual”.76
In 2012, the American Society of Clinical Oncology (ASCO) stated that PC should be integrated into cancer care for all patients with advanced or metastatic cancer.77 Model programs of research have consistently shown positive outcomes of integrated PC programs among patients with advanced cancer.77,78 Integrated PC programs integrate PC along with anticancer therapy from the time of diagnosis whereas non-integrated PC models introduce PC services much later in the diagnosis and with little collaboration between the oncologist and palliative team. However, the current state of PC availability and degree of integration of PC services into oncology practice at various cancer centers across the US are unknown.79  
Despite emerging evidence in the literature of its benefit, PC remains highly underutilized and providers typically wait to suggest PC until medical treatments are exhausted or death appears to be imminent.80,81,82,83 Consequently, many patients receive futile care at the end-of-life, resulting in ED admissions, many of which result in admission to or death in the inpatient unit or ICU.42,43 In 2008, Earle et al. provided a review of the literature to update analyses pertaining to the aggressiveness of cancer care near the end of life. Measures of aggressiveness of care included chemotherapy overuse near death and underutilization of hospice services. Based on Surveillance, Epidemiology and End Results (SEER) registries, 215,484 patients who died as a result of any malignancy of any duration between 1991 and 2000 were captured. The analyses indicated that intensity of care continues to increase. The proportion of patients still receiving chemotherapy within 14 days of death continues to rise from 9.7% in 1993 to 11.6% in 1999. Although hospice utilization is increasing, a large proportion of that increase indicated patients admitted to hospice within 3 days of death, accounting for 14.3% of all hospice admissions in 1999.84 
For patients with advanced cancer, the priority of the health care system  is to provide the most effective treatment for their cancer while incorporating palliative and other care services to maximize quality of life.85 PC outpatient clinics, inpatient consultation teams, PC units (PCUs) and hospices play an integral role in providing symptom control, psychosocial support and transition of care for patients with cancer and their families along the cancer care trajectory. PC’s offerings have led to both national and international organizations supporting early integration of PC into oncology practice.20,86–88 Model programs of research have consistently show positive outcomes of early integration of PC programs among patients with advanced cancer. Findings demonstrate that early incorporation of PC promotes pain and symptom relief, improves patient/caregiver/family satisfaction, facilitates earlier transition to hospice, decreases ED visits, lowers health care costs without affecting mortality and extends survival.6–10,89–91 On the other hand, the literature also demonstrates that delayed referral significantly limits the effectiveness of palliation.83,92,93  
In 2010, Hui, et al. published a study about the availability and integration of PC at US cancer centers. Of 71 NCI-designated cancer centers and 71 non-NCI designated cancer centers, most centers reported a PC program, however, the scope of services and the degree of integration varied widely.79 Despite growth in the number of PC programs in the US during the past decade94–97, the infrastructure and delivery of care remains heterogeneous. Three models of PC have been described in the literature, the Solo Practice Model, The Congress Practice Model and the Integrated Care Model.32 
In the Solo Practice Model, the oncologist takes care of all the primary disease assessment and management as well as the supportive/PC needs. This model is frequently required and common in private practices and small communities, where supportive/PC consultants are unavailable. This model has an advantage in that the patient receives all aspects of care from the same health care professional. However, disadvantages include time constraints and care from a provider who has little PC training98 and oncologist risk of burnout due to the need to assume all aspects of care.99
In the Congress Practice Model, the primary the oncologist refers the patient to multiple consultants. For example, a patient may be referred to a pain specialist for pain and a psychiatrist for emotional distress. The role of supportive/PC is limited to addressing end-of-life issues. The Congress Practice Model attempts to obtain care in an interdisciplinary fashion, however, the means in which it is executed can be both expensive and exhausting for the patient and family/caregivers. Furthermore, this model may even compromise optimal patient care in that poor communication and lack of interaction among multiple specialists taking care of one patient can result in adversary outcomes such as drug interactions and aggravation of one problem while trying to improve another problem.100 
The integrated approach is illustrative of the optimal delivery of supportive/PC.77 In the Integrated Care Model,32,79,101 the oncologist focuses primarily on the management of the cancer and the supportive/palliative team addresses the vast majority of physical and psychosocial concerns. While other specialists may be consulted to specific reasons, the majority of care in this model can be managed by a single supportive/PC team. The incorporation of a single supportive/PC team reduces the burden of number of visits as well as cost. When supportive/PC is integrated into the care of the patient, the oncologists can focus primarily on managing the cancer while the palliative team can address other issues that the patient may be experiencing. Collaboration among surgical, radiation and medical oncologists is common; however supportive/PC specialists can be incorporated into this model. 


















Models of Palliative Care Delivery
		
Solo Practice Model	Congress Practice Model	Integrated Care Model
Oncologist manages cancer care and supportive/palliative care needs	Oncologist refers the patient to multiple consultants for supportive/palliative care needs	Oncologist focusses primarily on the management of the cancer




Patient receives all aspects of care from same professional	Referrals to consultants to meet patients’ specific needs at that time	Majority of care can be managed by a single supportive/palliative care team
		
Minimal cost and time burden		Reduces the burden of number of visits and cost
		
		Oncologist can focus primarily on the cancer while palliative team can address physical and psychosocial issues
		




Time constraints 	Referral to multiple clinics with different appointments places additional time and financial burden on the patient	Limited penetration of this model among referring colleagues
		
Care from a provider with little palliative care training	Not all palliative care needs are assessed	
		
Oncologist risk of burnout due to the need to assume all aspects of care	Poor communication and lack of interaction among multiple specialists can lead to adversary outcomes (i.e. drug interactions)	
Not all palliative care needs are assessed		





One large urban practice of the University of Pittsburgh Cancer Institute (UPCI) Breast Program. Magee-Womens Hospital of the University of Pittsburgh Medical Center has been designated as a national Center for Excellence in Women's Health by the Office on Women's Health in the U.S. Department of Health and Human Services. Magee was one of the orignal six institutions to be awarded this distinction in 1996. The Women's Cancer Center of Magee Womens Hospital is a UPCI outpatient facility located within Magee-Womens Hospital. The Center offers comprehensive counseling and cancer treatment services including administration of chemotherapy, supportive cancer therapies, and psychological counseling and serves as the hub for breast cancer treatment within the city. In addition to the Hillman Cancer Center, housed on the UPCI campus, the Women’s Cancer Center of Magee is considered a flagship site for breast cancer. According to 2010 UPMC Facilities Reportable Cases, the Women’s Cancer Center of Magee Womens Hospital saw 1,355 breast cancer cases, or 48.5% of breast cancer cases within the UMPC network. Of these 1,355 cases, 31 cases were classified as Stage IV or metastatic upon presentation or referral. The high number of breast cancer cases and flagship status of the Women’s Cancer Center of Magee Womens Hospital made this an ideal site for examining the reason for and utilization of the ED among women with metastatic breast cancer at the end of life.
3.2	Population/subjects
The population consisted of a cohort of MBC patients who died between January 2010 and May 2012. Using an established MBC database at the designated UPCI site, cease to breath (CTB) dates were organized in descending order from 2012 to 2010, resulting in 100 patients.
3.3	Data collection
The development of a protocolized abstraction method was necessary prior to submitting the protocol to the University of Pittsburgh institutional review board (IRB). Through collaboration with an oncology nurse practitioner, specializing in the care of women with breast cancer, a set of variables as well as methods to collect data for those variables was established. The following information was extracted from the medical records: patients’ demographic characteristics (age at MBC, race, zipcode, insurance), total length of survival, length of metastatic survival, use of chemotherapy in the last 6 months of life, total number of metastatic chemotherapy lines received, PC characteristics (enrollment and total visits), ED characteristics (utilization, frequency, outcome, reason) and acute care death. Health insurance for breast cancer treatment in Pennsylvania is guaranteed for all women of low or moderate income who are diagnosed with breast cancer through the Commonwealth of Pennsylvania’s Breast and Cervical Cancer Prevention and Treatment Program. Thus, insurance was not a reliable indicator of access to resources. Once the protocolized abstraction was developed and eligible. patient records were identified, we began the retrospective chart review of deceased MBC patients.  Data were abstracted for each subject and entered into Excel©. 
3.3.1	Outcomes
ED Frequency: Frequency was measured by tallying the total number of ED visits in the last 6 months of life. The number of ED visits was abstracted from the electronic medical record. Documentation of ED visit(s) was collected from the electronic medical record. 
Reason for ED visit(s): Reason for ED visit was measured by coding each visit according to one of the following categories: 1) Infection; 2) Cardiopulmonary; 3) Pain; 4) Nausea/Vomiting/Dehydration; 5) Neurological; 6) Miscellaneous. Documentation of reason for ED visit(s) was collected from the electronic medical record. 
Outcome of ED visit(s): Outcome of ED visit was measured by coding each ED visit according to 1) Discharge or 2) Admission. Documentation of outcome of ED visit(s) was be collected from the electronic medical record. 
Number of ED visit(s) within 7 days of chemotherapy: Number of ED visit(s) within 7 days of chemotherapy was measured by examining the date of ED presentation and examining the chemotherapy record to see if chemotherapy was administered within 7 days of presentation in the ED. Documentation of chemotherapy was collected from the paper chart and documentation of ED visit(s) was collected from the electronic record. 
Chemotherapy Utilization: Chemotherapy utilization was measured by tallying the total number of chemotherapy lines received throughout the duration of the metastatic diagnosis. Documentation of chemotherapy was collected from the paper chart. 
Acute Care Death: Acute care death was measured by determining the total number of acute care deaths. Acute care deaths were coded according to 1) hospital inpatient unit or 2) ICU. Documentation of acute care death was collected from the electronic medical record. 
3.4	Analysis
A convenience sample resulted from patients deceased between 2010 and 2012. Due to the investigative nature of this study, no previous effects have been reported and therefore an analysis of sample size or power could not be achieved. 
3.4.1	Key Independent Variables
A specific area of interest was related to the relationship between age, race, income and acute care utilization. Of additional interest was the relationship between utilization of outpatient PC and acute care utilization. 
Age: Subject age (years) at MBC diagnosis was collected from the paper chart or electronic medical record. Age was collected and reported in years. 
Race: Subject self-reported race was collected from the paper chart or electronic medical record. Race was categorized according to 1) White; 2) African American.
Income: Subject income (median income) was determined by zip code using census statistics from www.zipwho.com.
Palliative Care Status: Subject PC status was collected from the paper chart or the electronic medical record. PC status was categorized according to: 1) Yes; 2) No.
4.0 	Statistical analysis
A convenience sample resulted from patients deceased between January 2010 and May 2012. Due to the investigative nature of this study, no previous effects have been reported and therefore an analysis of sample size or power could not be achieved. Of primary interest were the general ED utilization patterns (utilization, frequency, outcome, reason) of women with MBC during their last 6 months of life. An additional area of interest was related to utilization of outpatient PC. Patients were categorized into one of two groups: those with documentation of one or more outpatient PC visit(s) to or into those with no documentation of PC visit. 
Descriptive statistics were used to summarize the patient and demographic characteristics, lengths of survival, chemotherapy use, PC characteristics, ED characteristics and location of death. 
For Aim 2, multiple regression was employed to test associations between age, race and income on each of the explored factors.
For Aim 3, multiple regression was employed to test associations between PC status on each of the explored factors. Age at MBC diagnosis, household income, and race were entered first and modeled as covariates, removing any variability due to these factors from the overall model. Main effects of PC status were then examined within the model to determine any significant differences between these two types of care groups. Statistical Package for the Social Sciences, Version 20 (SPSS, Inc., Chicago, Il) was used for all analyses. 
5.0 	results
5.1	aim 1

























Median income (as determined by zip code)	$39,425/year
Disease Characteristics	N=100 (%)
SURVIVAL
Median total MBC survival (months)	28.0
METASTATIC SITES
Average number of sites	2.9 (SD=1.2)
PALLIATIVE CARE
Enrolled in outpatient palliative care	15 (15)
Acute Care Characteristics	N=100 (%)
CHEMOTHERAPY (n=67)
Average number of metastatic lines	3.6 (SD= 2.4)
Received chemotherapy in last 6 months of life	52 (52)
EMERGENCY DEPARTMENT 
Documentation of one or more visits	69 (69)
Total number of visits	190
Average number of visits	2.8 (SD=1.7)





Between the years of 2010 and 2012, there were 100 deceased MBC patients at the NCI designated cancer site. 100% of the cohort was female (n=100) with a mean age of 53.7 years (SD=12.4) at MBC diagnosis. The majority (n=90) of the sample was white and had private insurance (n=54). The median income, as determined by zip code, was $39,425/year.  Only 15% (n=15) were enrolled in outpatient PC. 
5.1.2	Disease Characteristics
Median total survival was 28.0 months, the average number of metastatic sites was 2.9 (SD=1.2). 15% of the cohort (n=15) had documentation of one or more outpatient PC visit(s). 
5.1.3	Acute Care
5.1.3.1	Chemotherapy
As expected with this patient population, chemotherapy utilization near the end of life was very common. Of patients whose chemotherapy record was available (n=67), a total of 3.6 (SD=2.4) sequential lines of metastatic chemotherapy were received. 78% (n=52) of patients received chemotherapy in the last six months of life. When assessing the relationship between ED utilization and chemotherapy, those patients on active chemotherapy in the last six months of life were more likely than their non-chemotherapy counterparts to visit the ED. Patients receiving chemotherapy in the last six months of life had an average of 2.38 (SD=2.1) visits versus their non-chemotherapy counterparts who had an average of .80 (SD=0.9) visits; p=.000.  Furthermore, when assessing the temporal relationship between chemotherapy administration and ED visits among women with MBC during the last six months of life 47% (n=32) of visits occurred within 7 days of chemotherapy. See Figure 2. 

Figure 2: Relationship between Chemotherapy and Emergency Department Visits
5.1.3.2	ED utilization
ED visits among this population were very common. Sixty nine percent (n=69) of patients had documentation of ED utilization in the last six months of life, accounting for a total of 190 visits, or 2.8 (SD=1.7) visits per patient. Of 190 visits, the majority (73%) resulted in admission to the hospital. See Figure 3. ED events varied among the 190 visits. ED events were categorized according to six selected codes: 1) infection; 2) cardiopulmonary; 3) pain; 4) nausea/vomiting/dehydration; 5) neurological and 6) other. The three most common reasons for ED presentation included cardiopulmonary (29%), nausea/vomiting/dehydration (19%) and neurological (18%). See Figure 4. Of 190 ED events, 73% (n=138) resulted in admission to the hospital, with cardiopulmonary visits contributing to the majority of hospitalizations. See Figure 5. 

Figure 3: Emergency Department Outcomes


Figure 4: Reasons for Emergency Department Visits

Figure 5: Reason for Admission to the Hospital from the Emergency Department 
5.1.3.3	Acute Care Death
Twenty six percent (n=26) patients died in the acute care setting; 13% (n=13) of deaths occurred in the hospital inpatient unit and 13% (n=13) of deaths occurred in the ICU. 

5.2	Aim 2
Aim 2 of this study sought to examine the influence of age, race and income on acute care utilization among women with MBC during the last six months of life. There was no significant relationship among sociodemographic variables and acute care utilization, except between age and ED visits. See Table 2. When examining the influence of age on ED utilization, there was a negative relationship, suggesting that older women had less ED visits than younger women.          (β=-0.199, t=-2.004, p=0.048).
Table 2: Influence of Age, Race and Income on Acute Care Utilization
Aim 2: Influence of age race and income on acute care Utilization	β	t	p
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Aim 3 of this study sought to compare acute care utilization in the last six months of life according to patients enrolled in outpatient PC and those not enrolled in outpatient PC. See Table 3.

Table 3: Influence of Palliative Care on Acute Care Utilization
Aim 3: Influence of PC on Acute Care Utilization	β	t	p
Chemotherapy 			
ED visits within 7 days of chemotherapy	.170	.636	.535
Chemotherapy utilization	.151	1.171	.246
ED Utilization 			














Patients enrolled in PC (n=15) used an average of 3.2 (SD=0.7) lines of chemotherapy and those not in PC (n=85) used 3.7 (SD=0.3) lines. No significant relationship was found between PC status and chemotherapy utilization, after controlling for subject’s age at MBC diagnosis, median income and race (β0.151, p=0.246). The temporal relationship between chemotherapy administration and ED visits among women with MBC during the last six months of life was assessed. There was no significant relationship between ED admission within the last 7 days of chemo between PC and non PC groups after controlling for subject’s age at MBC diagnosis, median income and race (β=0.170, p=0.535). 
5.3.2	ED Utilization
When examining utilization of the ED in the last six months of life between the PC and non-PC groups, the PC group had a mean of 2.6 (SD=1.7) visits and the non-PC group had a mean of 1.8 (SD=1.9) visits. No significant difference in ED utilization between PC and non-PC groups, no differences were noted after controlling for subject’s age at MBC diagnosis, median income and race (beta=-0.132, p=1.96). 
5.3.3	Acute Care Death
When comparing frequency of dying in the hospital inpatient unit or the ICU, no significant difference was noted between PC and non-PC patients. PC patients had two (13%) hospital inpatient deaths and two (13%) ICU deaths whereas their non-PC counterparts had 11 (13%) hospital inpatient deaths and 11 (13%) ICU deaths. No significant difference was noted in number of hospital deaths between PC and non PC groups after controlling for subject’s age at MBC diagnosis, median income and race. (β = 0.25. p=0.811). Additionally, there was no significant difference in the number of ICU deaths between PC and non PC groups (β=0.24, p=0.818). 
6.0 	Discussion
The purpose of our study was to describe characteristics and acute care utilization of women with metastatic breast MBC during the last six months of life. The results from this investigation provide three key findings. First, utilization of acute care services, including ED and chemotherapy, at the end of life is great among women with metastatic breast cancer. Secondly, younger women appeared to use the ED more frequently than older women. Finally, although a small sample size, non-integrated PC did not appear to have an impact on acute care utilization. 
The findings of this investigation mirror the current literature. In the United States, EDs are increasingly utilized by patients with cancer for disease or treatment related problems,42,43 with advanced and end-stage disease patients in need of symptom management and pain relief presenting to the ED most frequently.39,44–46 
While integrated models of PC have demonstrated pain and symptom relief, improved patient/caregiver/family satisfaction, earlier transition to hospice, decreased ED visits and other acute care utilization, lower health care costs, and extended survival,6–10 adoption of an integrated model is challenging among institutions, providers and patients. For patients with advanced cancer, the priority of the health care system is to provide the most effective treatment for their cancer while incorporating palliative and other care services to maximize quality of life.85Incorporation of an integrated care model in which palliative specialists are routinely involved in care may ensure a more comprehensive PC approach and may yield less utilization of acute care at the end of life. It can also be instrumental in providing guidance to breast cancer clinicians or more tailored patient and family counseling in order to prevent or limit ED visits. 
7.0 	Implications

These results have implication for 1) greater attention to quality of life endpoints, 2) creation of randomized controlled trials evaluating efficacy of sequential MBC therapies, 3) patient-provider discussion of prognosis, goals of care and end of life wishes.  

8.0 	Limitations
There are limitations to this investigation. The first limitation is in regards to the sample size. While we expected to find significant differences between PC and non-PC, however we did not. This could be attributed to the small sample size; there were only 15 PC subjects compared to 85 non-PC subjects. This skewed distribution makes the PC sample potentially too small to identify an effect. Even if there was a significant difference, it would be difficult to detect given the population. 
The second limitation is related to the model of PC delivery. This investigation looked at PC utilization at one NCI designated cancer setting. While there is a PC program in place at this designated center, the extent to which it operates is congruent with the Congress Practice Model. As presented in Figure 1, the Congress Practice Model is one in which the oncologist refers the patient to multiple consultants based on PC needs. Therefore, PC in this setting is limited and does not necessarily encompass nor reflect all of the features of an integrated PC model.  
9.0 	conclusion
There have been few similar studies to date to characterize a population-based sample of patients with cancer who use the ED. This study is unique in that it examines client and system characteristics and their influence on ED outcomes in a cohort of patients with MBC, some of whom received PC delivered on an “as needed basis” or congruent with the Congress Model and outcomes versus those who did not receive any PC intervention. 
To date, several studies6–10 have documented that earlier PC can improve patients’ quality of life, and, in some cases, improve survival. Still, obstacles exist to broadening the adoption of PC. Although it is unlikely that any single study will dramatically change the utilization of PC in oncology, identifying barriers to integration on a system level and barriers to acceptance on a client level are critical in bridging the gap between quality oncology care and quality PC. 
A large barrier to integration originates in the clinic where there is a high level of resistance to earlier PC and the false associations that PC and hospice care are synonymous with “lack of hope.” Encouraging providers to educate their patients and families on the benefits associated with PC while emphasizing that it is not a “one or the other” approach, meaning, PC can be delivered in conjunction with quality oncology care may help to encourage higher PC enrollment among patients with advanced stage cancer. 
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